Biomarkers of platelet activation in acute coronary syndromes
- 1 January 2012
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 108 (12) , 1109-1123
Abstract
The most convincing evidence for the participation of platelets in arterial thrombosis in humans comes from studies of platelet activation in patients with acute coronary syndromes (ACS) and from trials of antiplatelet drugs. Both strongly support the concept that repeated episodes of platelet activation over the thrombogenic surface of a vulnerable plaque may contribute to the risk of death from coronary causes. However, the relation of in vivoplatelet activation and adverse clinical events to results of platelet function tests remains largely unknown. A valuable marker of in vivoplatelet activation should be specific, unaltered by pre-analytical artefacts and reproducibly measured by easily performed methods. This article describes current biomarkers of platelet activation in ACS, reviews their advantages and disadvantages, discusses their potential pitfalls, and demonstrates emerging data supporting the positive clinical implications of monitoring in vivo platelet ac- tivation in the setting of ACS.Keywords
This publication has 181 references indexed in Scilit:
- An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate end‐pointsBritish Journal of Clinical Pharmacology, 2012
- Differential contributions of monocyte‐ and platelet‐derived microparticles towards thrombin generation and fibrin formation and stabilityJournal of Thrombosis and Haemostasis, 2011
- Existence of a microRNA pathway in anucleate plateletsNature Structural & Molecular Biology, 2009
- Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary interventionHeart, 2007
- Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart diseaseClinical Cardiology, 2007
- Genetic Polymorphisms of Platelet Glycoprotein Ia and the Risk for Premature Myocardial InfarctionJACC, 2006
- Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb‐IIIa antagonistsJournal of Thrombosis and Haemostasis, 2004
- A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion FormationJournal of Experimental Medicine, 2002
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusNew England Journal of Medicine, 1990
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986